Literature DB >> 23054750

The contribution of the cone beam Kv CT (CBKvCT) to the reduction in toxicity of prostate cancer treatment with external 3D radiotherapy.

Antonio José Conde-Moreno1, Carlos Ferrer-Albiach, Mercedes Zabaleta-Meri, Xavi J Juan-Senabre, Agustín Santos-Serra.   

Abstract

OBJECTIVE: Show that verification through cone beam Kv CT (CBKvCT) in a series of patients treated with 3D external radiotherapy (3DRT) for prostate cancer (PC) is related to a reduction in acute and late toxicity levels. MATERIALS AND
METHOD: A retrospective, non-randomized study of two homogeneous groups of patients treated between 2005 and 2008, 46 were verified using electronic portal devices (EPIDs) and 48 through CBKvCT. They received 3DRT for localized PC (T1-T3N0M0) and were prescribed the same doses. Treatment was simulated and planned with the same criteria with the same equipment with a median follow-up time of 24 months (12-54 months). Urinary and gastrointestinal toxicity was determined using Common Toxicity Criteria scale, version 4 and RTOG scales. Statistical analysis of data was performed where p < 0.005 being significative. RESULTS AND DISCUSSION: With an overall median follow-up time of 24 months, the levels of proctitis were, respectively, 19.56, 15.21 and 15.2 % in the first group, compared with 4.17, 2.08 and 8.33 % in the second. Statistically, less total and late proctitis, late rectal bleeding, anal fissure, total and acute haematuria, total and acute urinary frequency and total urinary incontinence was observed. No statistically significant evidence of a lowering in toxicity neither in terms of acute and late dysuria nor of a relationship to the TNM, Gleason or PSA or in the grade of stability.
CONCLUSION: Verification through CBKvCT in this series is associated with a statistically significant lowering toxicity. This justifies its use. Greater monitoring would be necessary to assess the impact of verification at the level of biochemical control.

Entities:  

Mesh:

Year:  2012        PMID: 23054750     DOI: 10.1007/s12094-012-0871-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  65 in total

1.  Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer.

Authors:  Stephanie T H Peeters; Joos V Lebesque; Wilma D Heemsbergen; Wim L J van Putten; Annerie Slot; Michel F H Dielwart; Peter C M Koper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-18       Impact factor: 7.038

2.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

Authors:  M J Zelefsky; Z Fuks; M Hunt; H J Lee; D Lombardi; C C Ling; V E Reuter; E S Venkatraman; S A Leibel
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

3.  Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy Intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study.

Authors:  Howard M Sandler; Ping-Yu Liu; Rodney L Dunn; David C Khan; Scott E Tropper; Martin G Sanda; Constantine A Mantz
Journal:  Urology       Date:  2010-02-13       Impact factor: 2.649

4.  Diabetes mellitus: a predictor for late radiation morbidity.

Authors:  D M Herold; A L Hanlon; G E Hanks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-02-01       Impact factor: 7.038

5.  Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists.

Authors:  Geert M Villeirs; Koenraad L Verstraete; Wilfried J De Neve; Gert O De Meerleer
Journal:  Radiother Oncol       Date:  2005-07       Impact factor: 6.280

6.  Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer.

Authors:  M J Zelefsky; Z Fuks; L Happersett; H J Lee; C C Ling; C M Burman; M Hunt; T Wolfe; E S Venkatraman; A Jackson; M Skwarchuk; S A Leibel
Journal:  Radiother Oncol       Date:  2000-06       Impact factor: 6.280

7.  Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms.

Authors:  A Jackson; M W Skwarchuk; M J Zelefsky; D M Cowen; E S Venkatraman; S Levegrun; C M Burman; G J Kutcher; Z Fuks; S A Liebel; C C Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-01       Impact factor: 7.038

8.  Correlation between acute and late toxicity in 973 prostate cancer patients treated with three-dimensional conformal external beam radiotherapy.

Authors:  Barbara A Jereczek-Fossa; Dario Zerini; Cristiana Fodor; Luigi Santoro; Flavia Serafini; Raffaella Cambria; Andrea Vavassori; Federica Cattani; Cristina Garibaldi; Federica Gherardi; Annamaria Ferrari; Bernardo Rocco; Epifanio Scardino; Ottavio de Cobelli; Roberto Orecchia
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-03       Impact factor: 7.038

9.  Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer.

Authors:  Abrahim Al-Mamgani; Wim L J van Putten; Wilma D Heemsbergen; Geert J L H van Leenders; Annerie Slot; Michel F H Dielwart; Luca Incrocci; Joos V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-19       Impact factor: 7.038

10.  Locally advanced prostatic cancer: long-term toxicity outcome after three-dimensional conformal radiation therapy--a dose-escalation study.

Authors:  M J Zelefsky; Z Fuks; T Wolfe; G J Kutcher; C Burman; C C Ling; E S Venkatraman; S A Leibel
Journal:  Radiology       Date:  1998-10       Impact factor: 11.105

View more
  2 in total

1.  The Usefulness of Adaptative Radiotherapy in Prostate Cancer: How, When, and Who?

Authors:  Rodrigo Muelas-Soria; Rafael García-Mollá; Virginia Morillo-Macías; Jorge Bonaque-Alandí; Patricia Sorribes-Carreras; Francisco García-Piñón; Carlos Ferrer-Albiach
Journal:  Biomedicines       Date:  2022-06-13

Review 2.  A Ten-year-long Update on Radiation Proctitis Among Prostate Cancer Patients Treated With Curative External Beam Radiotherapy.

Authors:  Gianluca Ferini; Stefano Pergolizzi
Journal:  In Vivo       Date:  2021-04-28       Impact factor: 2.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.